Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer.

British journal of cancer ·Vol. 94 ·No. 10 ·2006-05-22 ·Pages 1550-2

Banna GL, Aversa SM, Crivellari G, Ghiotto C, Chiarion-Sileni V, Monfardini S

Abstract

暂无摘要

MeSH Terms

Adult Antibodies, Monoclonal/administration & dosage Antibodies, Monoclonal, Humanized Antibody-Dependent Cell Cytotoxicity/drug effects Antineoplastic Agents/administration & dosage B-Lymphocytes/drug effects Breast Neoplasms/immunology,secondary,therapy Female Graft vs Tumor Effect Hematopoietic Stem Cell Transplantation Humans Middle Aged Receptor, ErbB-2/immunology,metabolism T-Lymphocytes/drug effects Trastuzumab

Chemicals

Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Receptor, ErbB-2 Trastuzumab

Authors & Affiliations

6 authors, click to expand affiliations / ORCID

Banna G L

Aversa S M L

Crivellari G

Ghiotto C

Chiarion-Sileni V

Monfardini S

References (9)

9 references, click to expand

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
Br J Cancer. 2006 Jan 30;94(2):259-67 PMID: 16404427
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Cancer Res. 2001 Feb 1;61(3):880-3 PMID: 11221874
HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
J Immunol. 2003 Aug 15;171(4):2161-9 PMID: 12902523
Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes.
Br J Cancer. 2002 Jul 1;87(1):21-7 PMID: 12085250
Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study.
Clin Cancer Res. 2003 Jul;9(7):2440-6 PMID: 12855616
Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells.
Cancer Res. 2002 Apr 15;62(8):2244-7 PMID: 11956077
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.
Clin Cancer Res. 2004 Sep 1;10(17):5650-5 PMID: 15355889
Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
Haematologica. 2004 May;89(5):599-605 PMID: 15136224
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.
J Clin Oncol. 2002 Jun 1;20(11):2624-32 PMID: 12039923

Article Info

Journal

British journal of cancer

Abbr.

Br J Cancer

ISSN

0007-0920

DOI

10.1038/sj.bjc.6603114

Published

2006-05-22

Pages

1550-2

Language

English

Region

England

NLM ID

0370635

PMCID

PMC2361276

Subset

Corrections

CommentOn

PMID: 16404427

External Links

PubMed source DOI: 10.1038/sj.bjc.6603114 PMC Full Text View journal details

Analysis Services

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer.

Contact

WeChat Official Account